2023-03-08 10:08:08 ET
- RenovoRx <<RNXT>> announces promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer (LAPC).
- The interim analysis suggests a 6-month potential improvement in median overall survival with RenovoGem, pending ongoing clinical investigation.
- The study compares treatment with RenovoTAMP versus standard of care systemic intravenous (“IV”) administration of gemcitabine and nab-paclitaxel, which has a seven-week survival benefit.
- The study is designed to randomize 114 patients (57 in each arm). The TIGeR-PaC Data Monitoring Committee (“DMC”) met and determined the interim data is promising and warrants continuation of this pivotal trial.
- The median overall survival in the IV gemcitabine and nab-paclitaxel control arm was 10 months, versus 16 months in the intra-arterial RenovoGem arm.
- This first-of-two interim analyses indicates that the TIGeR-PaC study is on track to demonstrate increased lifespan for patients being treated with RenovoGem for LAPC.
- Full data from the first interim analysis of the TIGeR-PaC study will be presented at the American Association of Cancer Research (AACR) Annual Meeting, April 17, 2023.
For further details see:
RenovoRx's late-stage RenovoGem study shows promising data for pancreatic cancer